A first-in-human, single-ascending dose trial of PRS-060 for the treatment of asthma

Trial Profile

A first-in-human, single-ascending dose trial of PRS-060 for the treatment of asthma

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs PRS 060 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Dec 2017 According to a Pieris Pharmaceuticals media release, the company has received approval from the Human Research Ethics Committee and authority from the Therapeutic Goods Administration to initiate this trial.
    • 08 Nov 2017 According to a Pieris Pharmaceuticals media release, dosing of the first subject will trigger a milestone payment of $12.5 million by AstraZeneca to Pieris.
    • 09 Aug 2017 According to a Pieris Pharmaceuticals media release, this trial is planned to conduct under a clinical trial notification to the Therapeutic Goods Administration in Australia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top